Jennifer Green

20PUBLICATIONS

142CO-AUTHORS

Epidemiological modellingExercise physiologyBehavioural epidemiologyCharacterisation of biological macromoleculesPharmacogenomics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|Jun 05, 2026

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

|Mar 31, 2026

Fat, muscle, and anti-obesity medications in cardiovascular disease prevention.

Muhammad Shahzeb Khan, Muhammad Hamza Dawood, Yehuda Handelsman

|Mar 29, 2026

Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

Rajiv Agarwal, Ricardo Correa-Rotter, Sankar D Navaneethan

|Nov 06, 2025

Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.

Amy Mottl, Charlie Scott, Jennifer B Green

|Sep 23, 2025

Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.

Rodica Pop-Busui, Samuel P Rosin, Nicole M Butera

|Sep 19, 2025

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).

Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink

Pageof 4

Frequent Collaborators

Muthiah Vaduganathan

Julio Rosenstock

Amy Mottl

Rajiv Agarwal

Peter Rossing

Rodica Pop-Busui

Hiddo J L Heerspink

Janet B McGill

Masaomi Nangaku

Charlie Scott

Frequent Collaborators

Muthiah Vaduganathan

Julio Rosenstock

Amy Mottl

Rajiv Agarwal